During the past decade, Hamatologische/Onkologische Gemeinschaftspraxis - Augsburg conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 8 clinical trials were completed, i.e. on average, 114.3% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 7 clinical trials were completed. i.e. 350% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hamatologische/Onkologische Gemeinschaftspraxis - Augsburg" #1 sponsor was "Hoffmann-La Roche" with 5 trials, followed by "German High-Grade Non-Hodgkin's Lymphoma Study Group" with 3 trials sponsored, "Clovis Oncology, Inc." with 2 trials sponsored, "Egetis Therapeutics" with 2 trials sponsored and "Eli Lilly and Company" with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hamatologische/Onkologische Gemeinschaftspraxis - Augsburg" #1 collaborator was "Foundation Medicine" with 2 trials as a collaborator, "NSABP Foundation Inc" with 2 trials as a collaborator, "Solasia Pharma K.K." with 2 trials as a collaborator, "German Breast Group" with 1 trials as a collaborator and "German CLL Study Group" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Hamatologische/Onkologische Gemeinschaftspraxis - Augsburg" are "Breast Cancer" (4 trials), "Chronic Lymphocytic Leukemia" (3 trials), "Colorectal Cancer" (3 trials), "Lymphoma" (3 trials) and "Chemotherapy-induced Peripheral Neuropathy" (2 trials). Many other conditions were trialed in "Hamatologische/Onkologische Gemeinschaftspraxis - Augsburg" in a lesser frequency.

Most popular intervention types in "Hamatologische/Onkologische Gemeinschaftspraxis - Augsburg" are "Drug" (21 trials), "Biological" (6 trials), "Radiation" (4 trials), "Other" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "cyclophosphamide" (4 trials), "radiation therapy" (4 trials), "Cyclophosphamide" (3 trials), "doxorubicin hydrochloride" (3 trials) and "filgrastim" (3 trials). Other intervention names were less common.

The vast majority of trials in "Hamatologische/Onkologische Gemeinschaftspraxis - Augsburg" are 18 trials for "All" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Hamatologische/Onkologische Gemeinschaftspraxis - Augsburg". undefined are not yet recruiting, undefined are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Hamatologische/Onkologische Gemeinschaftspraxis - Augsburg, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Hamatologische/Onkologische Gemeinschaftspraxis - Augsburg, 1 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".